Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Drug ineffective, Suspected COVID-19
Clinical narrative: caught COVID after booster; caught COVID after booster; MARKETING PROGRAM NAME NOT AVAILABLE.  This is a solicited report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4349298-00 (AbbVie).  A 42-year-old female patient received BNT162b2 (BNT162B2), on 01Mar2021 as dose 1, single (Batch/Lot number: unknown), on 01May2021 as dose 2, single (Batch/Lot number: unknown) and on 01Dec2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 42 years, all intramuscular for covid-19 immunisation; adalimumab (HUMIRA), (Batch/Lot number: unknown) subcutaneous for psoriatic arthropathy. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "recovered" and all described as "caught COVID after booster". The action taken for adalimumab was unknown. Mar2022, patient experienced caught Covid after booster and between injection pain in neck, back and wrist with Humira (Adalimumab). On an unknown date, caught covid after booster resolved. Pfizer Biontech Covid-19 vaccine (Tozinameran) was also considered suspect. Solicited report from a consumer of an adult female with events of non-serious caught covid after booster and between injection pain in neck, back and wrist with Humira (Adalimumab). There was no reported medical history. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  The reporter's assessment of the causal relationship of "caught covid after booster" with the suspect product(s) BNT162b2 was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment.  Causality for Humira (Adalimumab): The reporter's causality for the event(s) of caught covid after booster with Humira (adalimumab) was no reasonable possibility. The reporter's causality for the event(s) of between injections pain in neck, back and wrist unknown onset, between injections pain in neck, back and wrist unknown onset, between injections pain in neck, back and wrist unknown onset and between injections pain in neck, back and wrist unknown onset was not provided.  Suspect Drug(S) (include generic name): Seq.No: 2 Drug: Pfizer Biontech Covid-19 Vaccine (tozinameran) (tozinameran), unknown, unknown, unknown, Causality:1) Covid-19 (covid-19), Action(s) taken with drug:  Unknown, Causality as per reporter (Drug/Vaccine):  possible, Dechallenge:  N/A Neck pain (Neck pain), Back pain (Back pain), Wrist pain (Arthralgia), Wearing off effect (Therapeutic response shortened) Action(s) taken with drug: Unknown, Causality as per reporter (Drug/Vaccine):  Not Reported, Dechallenge:  N/A. Suspect Drug(S) (include generic name): Seq. No: 1 Drug: Humira (adalimumab), unknown Causality: Covid-19 (covid-19), Action(s) taken with drug:  Unknown, Causality as per reporter (Drug/Vaccine):  No reasonable possibility, Dechallenge:  N/A, Neck pain (Neck pain), Back pain (Back pain), Wrist pain (Arthralgia), Wearing off effect (Therapeutic response shortened) Action(s) taken with drug: Unknown, Causality as per reporter (Drug/Vaccine):  Not Reported, Dechallenge:  N/A,  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the information currently available, lack of efficacy of the suspected vaccine BNT162B2 cannot be completely excluded